-

Bruker Launches X4 POSEIDON™ Advanced X-Ray Microscope for Three-Dimensional Microscopy in Industrial and Scientific Applications

KONTICH, Belgium--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announces the launch of the new X4 POSEIDON™, a high-performance 3D X-ray microscope (XRM) using micro-Computed Tomography (microCT). This innovative benchtop XRM system offers advanced capabilities comparable to larger, floor-standing systems to make high-resolution 3D X-ray microscopy accessible for demanding XRM applications in industrial applications and scientific research.

The X4 POSEIDON features a high-end X-ray source that improves 3D resolution more than an order of magnitude compared to similar instruments. The system offers a large field-of-view high-efficiency detector, which optionally can be combined with a high-resolution scientific CMOS detector for multi-vision analytical flexibility.

The X4 POSEIDON is powered by 3DxSUITE software, with automated protocols, an intuitive and customizable user interface, integrated database and user management, and multi-language support. Designed for low maintenance, the system enhances uptime and reduces cost of ownership. Options are field-upgradable, allowing for cost-effective expansion to meet evolving analytical needs and future innovations.

Diederik Ellerbroek, Bruker AXS Vice President for Materials Science XRM, stated: “The X4 POSEIDON represents a significant advancement in benchtop XRM design and performance. It offers flexibility and performance for fast 3D high-resolution XRM with a large field of view for industrial and materials science research applications in the geosciences, pharmaceutical R&D and QA/QC, composite materials, batteries, renewable energy, and microelectronics.”

Guillaume Tetard, Bruker Biospin Vice President for Optical and mCT Preclinical Imaging, added: “The X4 POSEIDON is a cutting-edge XRM system with unmatched image quality in its category for performance across life-science applications from bone and dental research, to soft tissue imaging, plant and animal biology.”

About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI and HPC. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

Contacts

Investor Contact:
Joseph Kostka
Director - Investor Relations
Bruker Corporation
T: +1 978 313-5773
E: Investor.Relations@bruker.com

Media Contact:
Markus Ziegler
Sr. Director and Head of Group Marketing
Bruker BioSpin
T: +49 172 3733531
E: pr@bruker.com

Bruker Corporation

NASDAQ:BRKR

Release Versions
$Cashtags
Hashtags

Contacts

Investor Contact:
Joseph Kostka
Director - Investor Relations
Bruker Corporation
T: +1 978 313-5773
E: Investor.Relations@bruker.com

Media Contact:
Markus Ziegler
Sr. Director and Head of Group Marketing
Bruker BioSpin
T: +49 172 3733531
E: pr@bruker.com

Social Media Profiles
More News From Bruker Corporation

Bruker Advances Single-Cell Proteomics and Immunopeptidomics Performance; Unveils New Proteomics Software and Applications for Enhanced Biological Insights at US HUPO

PHILADELPHIA--(BUSINESS WIRE)--At the 21st Annual US HUPO Conference, Bruker Corporation (Nasdaq: BRKR) announces significant advances in 4D-Proteomics™ performance, software and applications for deeper biological insights. A. AIP on timsTOF Ultra 2: Significantly improved peptide and protein identification performance for single-cell proteomics and immunopeptidomics (work-in-progress) The new AIP enables highly efficient ion transfer from the collision cell to the orthogonal acceleration regio...

Bruker Spatial Biology to Announce Groundbreaking Advances at AGBT 2025

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announced today that it will unveil significant advancements in spatial biology at the 2025 Advances in Genome Biology and Technology (AGBT) General Meeting. Bruker Spatial Biology will announce the following four innovations that underscore Bruker’s leading commitment to advancing spatial biology with pioneering, best-in-class platforms: the first and only Whole Transcriptome Panel (WTX) on the subcellular resolution CosMx Sp...

Bruker Appoints Laura Francis to its Board of Directors

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker’s Audit Committee as a financial expert after Bruker’s annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (Nasdaq: SIBN), a medical device company s...
Back to Newsroom